Stem Cell Therapy for Lungs Disease in Delhi, India

Causes

Chronic lung disease rarely has a single cause — it usually develops from a combination of long-term exposure, infection, and in some cases, genetic susceptibility.

Long-Term Exposure to Harmful Substances

Cigarette smoke is the single largest contributor to COPD and lung cancer worldwide. Beyond smoking, prolonged exposure to air pollution, occupational dust (coal, silica, asbestos), and chemical fumes can progressively damage lung tissue, leading to scarring and reduced elasticity — the hallmark of conditions like interstitial lung disease.

Infections

Repeated or severe respiratory infections — viral, bacterial, or fungal — can leave permanent scarring in lung tissue. Tuberculosis and severe pneumonia, in particular, are known to cause long-term structural damage even after the infection itself has resolved.

Genetic and Autoimmune Factors

Some individuals carry a genetic predisposition to lung disease. Alpha-1 antitrypsin deficiency, for example, significantly raises the risk of early-onset emphysema. Autoimmune conditions such as rheumatoid arthritis and scleroderma can also trigger inflammation and fibrosis within lung tissue, contributing to interstitial lung disease.

Idiopathic Causes

In idiopathic pulmonary fibrosis, as the name suggests, no single clear cause is identified — the lung tissue gradually thickens and scars through a process researchers believe involves abnormal wound-healing responses at the cellular level, which is part of what makes it a focus of regenerative medicine research.

Because these causes act on lung tissue differently — inflammation-driven in COPD and asthma, scarring-driven in IPF and ILD — treatment approaches, including regenerative options, are tailored to the specific underlying pattern of damage. This is explored further in the Treatment and Mechanism sections below.

Symptoms

Lung disease symptoms often develop gradually, which is why many patients don’t seek evaluation until the condition has progressed. Key warning signs include:

• Shortness of breath, especially during light activity or when lying flat
• Persistent or worsening cough, sometimes producing mucus or blood
• Wheezing, often mistaken for a minor respiratory irritation
• Chest tightness or pain, particularly during breathing
• Chronic fatigue — a lack of oxygen forces the body to work harder for everyday tasks
• Unexplained weight loss, common in advanced fibrotic lung disease
• Recurrent respiratory infections, indicating weakened lung defenses
• Clubbing of the fingers or toes, a sign associated with chronic low blood-oxygen levels in some forms of lung disease

Any of these symptoms — especially breathlessness that doesn’t improve with rest or a cough that persists beyond a few weeks — warrants prompt medical evaluation. Because many lung conditions overlap with cardiovascular symptoms, patients with breathlessness and fatigue are sometimes also evaluated for underlying cardiovascular disease as part of a complete workup.

Diagnosis

Accurately diagnosing the type and severity of lung disease requires a combination of imaging, functional testing, and sometimes direct tissue sampling.

• Chest X-ray — a quick, painless first step that can reveal obvious abnormalities such as scarring, fluid, or hyperinflated lungs.
• High-Resolution CT (HRCT) Scan — provides detailed cross-sectional images of lung tissue and is considered the gold standard for detecting the pattern of scarring seen in ILD and IPF.
• Pulmonary Function Tests (PFTs) — measure lung volume, airflow, and gas exchange efficiency, helping quantify how much function has been lost and how the disease is progressing.
• Six-Minute Walk Test — assesses how blood-oxygen saturation changes with exertion, a practical marker of real-world breathing capacity.
• Bronchoscopy — a thin camera is passed into the airways to directly visualize tissue and, if needed, collect a biopsy sample.
• Blood Tests — including autoimmune markers, which help identify whether an underlying connective tissue disease is contributing to lung damage.

These tests are generally safe, though CT imaging involves a small amount of radiation exposure, and bronchoscopy can cause temporary coughing or mild discomfort. Our medical team reviews this full diagnostic picture — alongside a physician consultation — to assess eligibility for stem cell treatment and to determine which delivery approach (see Implantation) is most appropriate for the specific disease pattern involved.

Treatment

Stem Cell Therapy for Lung Disease — How It Works

Stem cell therapy is a regenerative medicine approach that uses stem cells — most commonly mesenchymal stem cells (MSCs) — with the aim of supporting tissue repair, reducing inflammation, and improving the body’s own regenerative processes. In the lungs, which are constantly exposed to pollutants, smoke, and airborne pathogens, chronic inflammation and progressive scarring are central features of most forms of disease. Researchers are exploring whether MSCs, delivered into the bloodstream or directly toward lung tissue, can help modulate this inflammatory environment and support the lungs’ own repair mechanisms.

MSCs used in this research can be sourced from:

• Bone marrow — one of the earliest and most studied sources of MSCs
• Adipose (fat) tissue — a rich, relatively easy-to-access source of MSCs
• Umbilical cord tissue (Wharton’s Jelly) — collected non-invasively and considered highly suitable for laboratory expansion

Current published research — including early-phase trials in idiopathic pulmonary fibrosis and COPD — has explored safety, tolerability, and preliminary signals of benefit, such as improved six-minute walk distances or stabilized lung function. This remains an active and evolving area of investigation, with data from large-scale trials still limited (see Scientific References).

The general treatment pathway includes:

1. Eligibility Review — a full assessment of the patient’s diagnosis, imaging, pulmonary function results, and overall health.
2. Stem Cell Source Selection — determined by the physician based on the patient’s condition and treatment goals.
3. Laboratory Processing — cells are processed under GMP-compliant, quality-controlled laboratory conditions (see Quality Certificate).
4. Delivery — cells are administered via the method best suited to the patient’s condition (see Implantation).
5. Monitoring — structured follow-up to track respiratory function and any changes in symptoms over time.

Because stem cell therapy for lung disease remains investigational, it is generally considered as a complementary approach used alongside — not instead of — standard pulmonology care, including medications, oxygen therapy, and pulmonary rehabilitation. For more on how sample processing works, visit our Stem Cell Processing page.

Implantation

The route used to deliver stem cells is selected according to the specific lung condition, disease severity, and the patient’s overall clinical status. Delivery methods considered include:

• Intravenous (IV) infusion — the most common route, allowing cells to circulate systemically and reach the lungs via pulmonary blood flow.
• Inhalation-based delivery — an investigational method aimed at bringing cells more directly toward airway and alveolar tissue.
• Intra-arterial delivery — targets a specific vascular region when localized effect is desired.
• Intramuscular or subcutaneous injection — used in select supportive protocols.

The choice of method is made by the treating physician based on imaging findings, disease pattern (obstructive vs. fibrotic), and the patient’s tolerance for the procedure. To understand the science behind each delivery route in more depth, visit our page on Stem Cell Delivery Methods.

Improvements

Patients undergoing stem cell–based approaches for chronic lung disease have reported changes across several dimensions, including:

• Easier, less labored breathing during daily activity
• Reduced frequency or severity of coughing episodes
• Improved exercise tolerance and stamina
• A general sense of increased energy and reduced fatigue
• Greater comfort in performing routine tasks that previously caused breathlessness

These outcomes vary meaningfully from patient to patient, depending on the type of lung disease, its severity and duration, and individual biology — they are not guaranteed, and this remains an area of ongoing clinical research. For more on the broader regenerative science behind these observations, see How Stem Cell Therapy Works.

Mechanism

The regenerative approach explored for lung disease is built around autologous or allogeneic mesenchymal stem cells, evaluated through a structured process:

1. Baseline Assessment — blood tests, sputum analysis, and chest imaging are used to characterize the patient’s condition before treatment.
2. Source Extraction — stem cells are collected from bone marrow, adipose tissue, or an approved donor source, depending on the protocol selected.
3. Cell Processing — the overall procedure typically spans 7–8 hours: roughly 1–2 hours for extraction, 2–3 hours for laboratory isolation and processing, and the remainder for preparation and administration.
4. Implantation — once processed, cells are delivered back into the body using the method most appropriate to the patient’s lung condition and overall health (see Implantation).

Autologous approaches — using the patient’s own cells — are generally considered to carry a lower risk of immune rejection, since the body does not recognize the cells as foreign. To understand the underlying biological principles in more depth, visit our page on the Physiological Mechanism of Stem Cells.

Our Promise

Viezec works with a network of established regenerative medicine centers in India. Our commitment to every patient exploring stem cell therapy for lung disease includes:

• Ongoing support throughout consultation, hospitalization, and treatment
• Transparent, honest communication about what regenerative therapy can and cannot offer
• A multidisciplinary care team experienced in pulmonology and regenerative medicine
• Strict adherence to internationally recognized laboratory and safety standards
• Continued follow-up care to monitor progress after treatment

To understand why many international patients choose India for regenerative care, visit Why Stem Cell Therapy in India.

Treatment Results

Chronic Obstructive Pulmonary Disease (COPD) and related lung conditions are typically marked by progressive airflow limitation, chronic cough, and morning breathing difficulty, with symptoms that can worsen gradually over years. Among patients who have undergone stem cell therapy through our network, many have reported improvements in breathing comfort, reduced coughing frequency, and better overall stamina during daily activity.

Outcomes are not uniform — a smaller subset of patients, often those with more advanced disease or additional health complications, require closer post-treatment observation and a longer recovery timeline. This variability underscores why a thorough pre-treatment evaluation (see Diagnosis) is essential before determining eligibility. For visual patient accounts, see our YouTube channel.

Testimonials

Sameer A. – Karachi, Pakistan – February 2020 – ⭐⭐⭐⭐☆
“My chronic lung disease caused breathlessness. After Viezec’s stem cell therapy, I can breathe easier and walk longer distances.”

Linda M. – Cape Town, South Africa – June 2020 – ⭐⭐⭐⭐⭐
“I suffered from COPD for years. Post-treatment at Viezec, my lung function improved, and I feel more energetic every day.”

Hiroshi N. – Tokyo, Japan – December 2020 – ⭐⭐⭐⭐☆
“Lung scarring made my life difficult. Stem cell therapy at Viezec reduced my symptoms, and I now live more comfortably.”

Camila R. – São Paulo, Brazil – March 2021 – ⭐⭐⭐⭐⭐
“I struggled with asthma complications. After Viezec’s therapy, my breathing improved, and I rarely need inhalers anymore.”

Peter H. – Berlin, Germany – August 2021 – ⭐⭐⭐⭐☆
“Chronic bronchitis left me weak. Viezec’s stem cell treatment strengthened my lungs, and my cough reduced significantly.”

Aisha F. – Nairobi, Kenya – February 2022 – ⭐⭐⭐⭐⭐
“I had difficulty even climbing stairs. After therapy at Viezec, my lungs feel stronger, and my stamina has improved.”

Miguel L. – Mexico City, Mexico – July 2022 – ⭐⭐⭐⭐☆
“Lung disease limited my daily activities. Viezec’s stem cell therapy gave me better breathing control and reduced fatigue.”

Anna P. – Warsaw, Poland – April 2023 – ⭐⭐⭐⭐⭐
“I lived with pulmonary fibrosis for years. After treatment at Viezec, my condition stabilized, and I feel much healthier.”

Ibrahim D. – Doha, Qatar – October 2023 – ⭐⭐⭐⭐☆
“My breathing was labored and painful. Post stem cell therapy, I can manage daily tasks with more ease and confidence.”

Sofia J. – Buenos Aires, Argentina – May 2025 – ⭐⭐⭐⭐⭐
“Lung disease was stealing my independence. Thanks to Viezec’s stem cell therapy, I breathe better and enjoy life again.”

Treatment Disclaimer

Before undergoing this procedure, patients should understand that stem cell therapy remains an experimental, investigational approach and may not produce the desired effect in every case. Depending on individual evaluation, treatment may be declined, or the recommended protocol may be adjusted based on the patient’s health status.

Our priority is providing the safest, most current techniques available, in line with recognized international standards. As with any medical treatment, no outcome can be guaranteed — individual biology varies, and results differ from patient to patient even with similar diagnoses. No fetal or embryonic stem cells are used in any of our treatment protocols.